Skip to content
411 PRESS
WarningRecall #D-0405-2026Drug / Pharmaceutical

Teva Pharmaceuticals USA Recalls Octreotide Acetate for Injectable Suspension

Teva Pharmaceuticals USA, Inc · Class II — Moderate Risk

Assorted pharmaceutical pills and tablets — representative photo for FDA drug recall
An assortment of pharmaceutical pills (representative file photo). Specific recalled product: see recall details below. Photo: Michael Nutt / Wikimedia Commons (CC BY-SA 2.0).

Product Description

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial in Kit, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9259-08.

Reason for Recall

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

FDA Classification

Class II — Moderate Risk

A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

Distribution

Nationwide in the USA

Remedy

Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.

Independent news on labor, safety, and accountability.